Acumen Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Acumen Pharmaceuticals

08/11/2024 16:24

* Acumen Pharmaceuticals Inc  ABOS.OQ   ABOS.O  is expected
to show no change in quarterly revenue when it reports 
results on November 12 for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Acumen Pharmaceuticals
Inc is
for a loss of 36 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Acumen
Pharmaceuticals Inc is $11.00​, above​ its last closing price
of $3.17. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.28       -0.28      -0.34     Missed  -21.4
 Mar. 31 0001  -0.26       -0.26      -0.25     Beat    3.8
 Dec. 31 2023  -0.30       -0.26      -0.28     Missed  -7.7​
 Sep. 30 2023  -0.27       -0.27      -0.24     Beat    9.8
 ​​Jan.        -0.34       -0.35      -0.28     Beat    19.1
 1 0001                                                 
 Jan. 1 0001   -0.35       -0.35      -0.28     Beat    19.1​
 Dec. 31 2022              -0.26      -0.32     Missed  -25.3
 Sep. 30 2022  -0.19       -0.23      -0.26     Missed  -13.1
 This summary was machine generated November 8 at 16:24 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)